Generation of polyclonal antibody with high avidity to rosuvastatin and its use in development of highly sensitive ELISA for determination of rosuvastatin in plasma.

Chem Cent J · 2011 · PMC3149564 · PMID 21726466

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In clinical studies, ROS (1-80 mg) produced highly significant dose-dependent reductions in low-density lipoprotein cholesterol (up to 65%) and was well tolerated.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.